Shanghai Serum Bio-Technology Co., Ltd. (SHA:688163)
China
· Delayed Price · Currency is CNY 24.02
-0.25 (-1.03%)
At close: Mar 9, 2026
SHA:688163 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 196.21 | 194.92 | 190.13 | 174.21 | 207.5 | Upgrade
|
| Other Revenue | - | - | 0.02 | 0.01 | 1.19 | Upgrade
|
| Revenue | 196.21 | 194.92 | 190.14 | 174.22 | 208.69 | Upgrade
|
| Revenue Growth (YoY) | 0.66% | 2.51% | 9.14% | -16.52% | 12.46% | Upgrade
|
| Cost of Revenue | - | 45.8 | 49.84 | 33.5 | 36.33 | Upgrade
|
| Gross Profit | 196.21 | 149.11 | 140.3 | 140.72 | 172.36 | Upgrade
|
| Selling, General & Admin | - | 76.71 | 74.35 | 73.71 | 62.81 | Upgrade
|
| Research & Development | - | 23.84 | 30.41 | 15.46 | 25.76 | Upgrade
|
| Other Operating Expenses | 134.17 | 1.68 | 1.53 | 1.21 | 1.45 | Upgrade
|
| Operating Expenses | 134.17 | 102.96 | 107.08 | 90.28 | 90.34 | Upgrade
|
| Operating Income | 62.04 | 46.15 | 33.22 | 50.45 | 82.03 | Upgrade
|
| Interest Expense | - | -0.43 | -0.65 | -0.68 | -0.71 | Upgrade
|
| Interest & Investment Income | - | 6.12 | 10.62 | 16.3 | 1.48 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.03 | 0.12 | 0.49 | -0.12 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.3 | 0.23 | -0.25 | 0.42 | -0.3 | Upgrade
|
| EBT Excluding Unusual Items | 61.74 | 52.04 | 43.06 | 66.97 | 82.38 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -4.97 | 2.59 | 2.62 | -0.79 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.41 | -0.01 | -0.07 | -0.25 | Upgrade
|
| Other Unusual Items | - | 3.09 | -0.23 | 4.53 | 6.54 | Upgrade
|
| Pretax Income | 61.74 | 50.57 | 45.42 | 74.04 | 87.88 | Upgrade
|
| Income Tax Expense | 10.03 | 6.28 | 6.64 | 9.84 | 11.39 | Upgrade
|
| Earnings From Continuing Operations | 51.71 | 44.29 | 38.77 | 64.2 | 76.48 | Upgrade
|
| Net Income | 51.71 | 44.29 | 38.77 | 64.2 | 76.48 | Upgrade
|
| Net Income to Common | 51.71 | 44.29 | 38.77 | 64.2 | 76.48 | Upgrade
|
| Net Income Growth | 16.76% | 14.23% | -39.60% | -16.06% | 21.07% | Upgrade
|
| Shares Outstanding (Basic) | 108 | 108 | 108 | 102 | 81 | Upgrade
|
| Shares Outstanding (Diluted) | 108 | 108 | 108 | 102 | 81 | Upgrade
|
| Shares Change (YoY) | -0.27% | 0.30% | 5.70% | 25.24% | 0.46% | Upgrade
|
| EPS (Basic) | 0.48 | 0.41 | 0.36 | 0.63 | 0.94 | Upgrade
|
| EPS (Diluted) | 0.48 | 0.41 | 0.36 | 0.63 | 0.94 | Upgrade
|
| EPS Growth | 17.07% | 13.89% | -42.86% | -32.98% | 20.51% | Upgrade
|
| Free Cash Flow | - | -9.12 | 4.15 | 41.46 | 64.68 | Upgrade
|
| Free Cash Flow Per Share | - | -0.08 | 0.04 | 0.41 | 0.80 | Upgrade
|
| Dividend Per Share | - | 0.320 | 0.200 | 0.750 | 0.900 | Upgrade
|
| Dividend Growth | - | 60.00% | -73.33% | -16.67% | - | Upgrade
|
| Gross Margin | 100.00% | 76.50% | 73.79% | 80.77% | 82.59% | Upgrade
|
| Operating Margin | 31.62% | 23.68% | 17.47% | 28.96% | 39.30% | Upgrade
|
| Profit Margin | 26.36% | 22.72% | 20.39% | 36.85% | 36.65% | Upgrade
|
| Free Cash Flow Margin | - | -4.68% | 2.18% | 23.79% | 30.99% | Upgrade
|
| EBITDA | 81.4 | 65.5 | 49.46 | 64.43 | 96.15 | Upgrade
|
| EBITDA Margin | 41.48% | 33.61% | 26.01% | 36.98% | 46.07% | Upgrade
|
| D&A For EBITDA | 19.36 | 19.36 | 16.24 | 13.98 | 14.12 | Upgrade
|
| EBIT | 62.04 | 46.15 | 33.22 | 50.45 | 82.03 | Upgrade
|
| EBIT Margin | 31.62% | 23.68% | 17.47% | 28.96% | 39.30% | Upgrade
|
| Effective Tax Rate | 16.24% | 12.41% | 14.62% | 13.29% | 12.97% | Upgrade
|
| Revenue as Reported | - | 194.92 | 190.14 | 174.22 | 208.69 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.